SAS and Carolina partner to accelerate antiviral drug development


SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related:

UNC Alumni Premiere Their Movie Musical, Dreaming of an Oscar
Three years ago, a team of University of North Carolina students set out on a mission to win an Oscar. By creating an original movie...

Carolina Insider Podcast: Basketball's Big Week, Football Recap, Robbie Bach
Football's regular season came to a stunning end in Raleigh. The Tar Heels now look to a bowl game (3:18). UNC Basketball faces an important...

Alumnus Kimathi Muiruri becomes Carolina’s 54th Rhodes Scholar
UNC-Chapel Hill alumnus Kimathi Muiruri has received the prestigious Rhodes Scholarship, making him the 54th Tar Heel to be named a Rhodes Scholar. Muiruri, a...

UNC selected for esteemed national Innovation Corps program
The University of North Carolina at Chapel Hill has been selected as a National Science Foundation Innovation Corps site, part of a larger effort to...

SAS and Carolina partner to accelerate antiviral drug development


© 2005-2021 Tar Heel Times | Contact | Privacy Policy | Site Map | RSS | Did UNC Win?

Tar Heel Times is an unofficial resource for UNC fans and is not affiliated with the University of North Carolina.